Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD
OBJECTIVE:The aim of the present study was to determine the predictive value of olfactory dysfunction for the early development of a synuclein-mediated neurodegenerative disease in subjects with idiopathic REM sleep behavior disorder (iRBD) over an observational period of 5 years. METHODS:Thirty-fou...
Gespeichert in:
Veröffentlicht in: | Neurology 2015-02, Vol.84 (7), p.654-658 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | OBJECTIVE:The aim of the present study was to determine the predictive value of olfactory dysfunction for the early development of a synuclein-mediated neurodegenerative disease in subjects with idiopathic REM sleep behavior disorder (iRBD) over an observational period of 5 years.
METHODS:Thirty-four patients with polysomnography-confirmed iRBD underwent olfactory testing using the entire Sniffinʼ Sticks test assessing odor identification, odor discrimination, and olfactory threshold. Patients with iRBD were prospectively followed up over a period of 4.9 ± 0.3 years (mean ± SD). The diagnosis of neurodegenerative diseases was based on current clinical diagnostic criteria.
RESULTS:After 2.4 ± 1.7 years (mean ± SD), 9 patients (26.5%) with iRBD developed a Lewy body disease (6 Parkinson disease and 3 dementia with Lewy bodies). The entire Sniffinʼ Sticks test and the identification subtest had the same overall diagnostic accuracy of 82.4% (95% confidence interval66.1%–92.0%) in predicting conversion. The relative risk for a Lewy body disease in the lowest tertile of olfactory function was 7.3 (95% confidence interval1.8–29.6) compared with the top 2 tertiles.
CONCLUSIONS:Assessment of olfactory function, particularly odor identification, may help to predict the development of a Lewy body disease in patients with iRBD over a relatively short time period and thus to identify patients suitable for future disease modification trials. |
---|---|
ISSN: | 0028-3878 1526-632X |
DOI: | 10.1212/WNL.0000000000001265 |